11β hydroxysteroid dehydrogenase type 2 enzyme is expressed in normotensive and hypertensive patients with renal disease

Nephrology

Volumn 4, Issue 1-2, 1998, Pages 81-86

  Stein Oakley, Alicia N ^a,b   Maguire, Julie A ^a   Dowling, John ^b   Perry, Greg J ^b   Krozowski, Zygmunt ^c   Thomson, Napier M ^a,b  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

11 hydroxysteroid dehydrogenase type 2; Hypertension; Renal disease

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; COMPLEMENTARY DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY COLLECTING TUBULE; KIDNEY DISEASE; KIDNEY DISTAL TUBULE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031779587     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1998.tb00325.x     Document Type: Article

References (21)

1. Edwards CR, Stewart PM, Burt D et al. Localization of 11-beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986-9.
2. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-5.
3. Ulick S, Levine S, Gunczler P et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J. Clin. Endocrinol. Metab. 1979; 49: 757-63.
4. Stewart P, Wallace A, Valentino R, Burt D, Shackleton C, Edwards C. Mineralocorticoid activity of licorice: 11beta-hydroxysteroid dehydrogenase comes of age. Lancet 1987; 2: 821-4.
5. Phillips PA, Johnston CI. Hormones and the kidney. In: Whitworth JA, Lawrence JR. (eds) Textbook of Renal Disease, 2nd edn. Churchill Livingstone, New York, 1994; 33-47.
6. Walker B, Stewart P, Shackleton C, Padfield P, Edwards C. Deficient inactivation of cortisol by 11-beta-hydroxysteroid dehydrogenase in essential hypertension. Clin. Endocrinol. 1993; 39: 221-7.
7. Soro A, Ingram M, Tonolo G, Glorioso N, Fraser R. Evidence of coexisting changes in 11beta-hydroxysteroid dehydrogenase and 5-beta reductase activity in subjects with untreated essential hypertension. Hypertension 1995; 25: 67-70.
8. Iki K, Miyamori I, Hatakeyama H et al. The activities of 5 beta-reductase and 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Steroids 1994; 59: 656-60.
9. Macdonald G. High blood pressure. In: Whitworth JA, Lawrence JR. (eds) Textbook of Renal Disease, 2nd edn. Churchill Livingstone, New York, 1994; 429-50.
10. Whitworth JA, Stewart PM, Burt D, Atherden SM, Edwards CRW. The kidney is the major site of cortisone production in man. Clin. Endocrinol. 1989; 31: 355-61.
11. Vierhapper H, Derfler K, Nowotny P, Hollenstein U, Waldhausl W. Impaired conversion of cortisol to cortisone in chronic renal insufficiency - a cause of hypertension or an epiphenomenon? Acta Endocrinol. (Copenh) 1991; 125: 160-4.
12. Albiston A, Obeysekere V, Smith R, Krozowski Z. Cloning and tissue distribution of the human 11beta-hydroxysteroid dehydrogenase type II enzyme. Mol. Cell. Endocrinol. 1994 105: R11-17.
13. Wilson RC, Harbison MD, Krozowski ZS et al. Several homozygous mutations in the gene for 11-beta-hydroxysteroid dehydrogenase type 2 In patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1995; 80: 3145-50.
14. Wilson RC, Krozowski ZS, Li K et al A mutation in the HSD11b2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol. Metab 1995; 80: 2263-6.
15. Obeyesekere VR, Ferrari P, Andrews RK et al. The R337c mutation generates a high Km 11-beta-hydroxysteroid dehydrogenase Type II enzyme in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1995; 80: 3381-3.
16. Mune T, White PC. Apparent mineralocorticoid excess - genotype is correlated with biochemical phenotype. Hypertension 1996; 27: 1193-9.
17. Stewart PM, Krozowski ZS, Gupta A et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11-beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996; 347: 88-91.
18. Krozowski Z, Maguire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J. Clin. Endocrinol. Metab. 1995; 80: 2203-9.
19. Kyossev Z, Walker PD, Reeves WB. Immunolocalization of NAD-dependent 11β-hydroxysteroid dehydrogenase in human kidney and colon. Kidney Int. 1996; 49: 271-81.
20. Walker BR. Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: Implications for the pathophysiology of hypertension. Steroids 1994; 59: 84-9.
21. Takeda Y, Miyamori I, Iki K et al. Endogenous renal 11-beta-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension 1996; 27: 197-201.